Johnson & Johnson (NYSE:JNJ) Shares Acquired by KMG Fiduciary Partners LLC

KMG Fiduciary Partners LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 5.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,750 shares of the company's stock after acquiring an additional 2,025 shares during the quarter. KMG Fiduciary Partners LLC's holdings in Johnson & Johnson were worth $5,459,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. IFS Advisors LLC lifted its position in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after purchasing an additional 100 shares during the period. Highline Wealth Partners LLC acquired a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $31,000. RPg Family Wealth Advisory LLC purchased a new stake in shares of Johnson & Johnson in the third quarter valued at approximately $35,000. Mowery & Schoenfeld Wealth Management LLC raised its position in Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock worth $40,000 after acquiring an additional 91 shares in the last quarter. Finally, Activest Wealth Management acquired a new stake in Johnson & Johnson in the third quarter valued at $40,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of research analyst reports. Morgan Stanley increased their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an "equal weight" rating in a report on Wednesday, October 16th. Citigroup dropped their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating for the company in a report on Wednesday, December 11th. Royal Bank of Canada boosted their price target on Johnson & Johnson from $178.00 to $181.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 16th. Wells Fargo & Company lifted their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 16th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $174.29.

Johnson & Johnson Trading Down 0.5 %

Shares of NYSE:JNJ traded down $0.74 during midday trading on Friday, reaching $147.03. The company's stock had a trading volume of 10,678,393 shares, compared to its average volume of 6,880,262. The business has a 50 day moving average price of $148.51 and a 200 day moving average price of $156.03. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The firm has a market cap of $353.99 billion, a price-to-earnings ratio of 21.28, a price-to-earnings-growth ratio of 2.30 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.37%. Johnson & Johnson's payout ratio is currently 71.78%.

Insider Buying and Selling

In other news, Director Mark A. Weinberger bought 1,000 shares of the business's stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now owns 1,000 shares of the company's stock, valued at $147,220. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.